R
Roland E. Schmieder
Researcher at University of Erlangen-Nuremberg
Publications - 780
Citations - 85811
Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study.
Manish Saxena,Roland E. Schmieder,Ajay J. Kirtane,Felix Mahfoud,Felix Mahfoud,Joost Daemen,Jan Basile,Philipp Lurz,Philippe Gosse,Kintur Sanghvi,Naomi D.L. Fisher,Lars Christian Rump,Atul Pathak,Peter J. Blankestijn,Anthony Mathur,Yale Wang,Michael A. Weber,Andrew S.P. Sharp,Andrew S.P. Sharp,Michael J. Bloch,Neil C. Barman,Lisa Claude,Yang Song,Michel Azizi,Michel Azizi,Melvin D. Lobo +25 more
TL;DR: In this paper, a post-hoc analysis of the RADIANCE-HTN SOLO study was conducted to identify predictors of patients' response to renal denervation.
Journal ArticleDOI
Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
Peter Bramlage,Claudia Zemmrich,Reinhard G. Ketelhut,Wolf-Peter Wolf,Eva-Maria Fronk,Roland E. Schmieder +5 more
TL;DR: The authors' data confirm randomized trial data concerning safe and efficient blood pressure reduction using a fixed-dose combination of olmesartan 40 mg and HCTZ 12.5/25 mg in a large, unselected patient population, independent of physical activity level.
Journal ArticleDOI
Aliskiren: a clinical profile
TL;DR: Aliskiren fulfils key criteria for a new antihypertensive agent, notably effective blood pressure lowering as monotherapy and combination therapy, 24-hour blood pressure control, safety and tolerability end-organ protective effects, minimal drug interaction and efficacy during long-term use.
Journal ArticleDOI
Renal endothelial effects of antihypertensive therapy.
TL;DR: No critically contributes to renal perfusion and there is evidence of reduced but also of unchanged NO bioavailability in the renal vasculature of patients with arterial hypertension both from protein expression and functional studies.
Journal ArticleDOI
Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients
Matthias Huber,Heinz Völler,Stefanie Jakob,Rona Reibis,Van Do,Juliane Bolbrinker,Irina Zergibel,Roland E. Schmieder,András Treszl,Karl Wegscheider,Reinhold Kreutz +10 more
TL;DR: A genetic polymorphism in the angiotensin II type 2 receptor (AGTR2 +1675G/A) has been associated with left ventricular hypertrophy (LVH) but exhibits only a minor effect onleft ventricular geometry in women and none in men.